Erratum: In vitro activity of solithromycin against erythromycin-resistant streptococcus agalactiae (Antimicrobial Agents and Chemotherapy (2014) 58:3 (1693–1698) DOI: 10.1128/AAC.02210-13);In vitro activity of solithromycin against erythromycin-resistant Streptococcus agalactiae

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1693-1698

  Piccinelli, Giorgio ^a   Fernandes, Prabhavathi ^b   Bonfanti, Carlo ^a   Caccuri, Francesca ^a   Caruso, Arnaldo ^a   De Francesco, Maria Antonia ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Cempra Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; PENICILLIN DERIVATIVE; SOLITHROMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BROTH DILUTION; CONTROLLED STUDY; DISK DIFFUSION; DOUBLE DISK DIFFUSION; EPSILOMETER TEST; ERM B GENE; ERM TR GENE; GENE IDENTIFICATION; GENOTYPE; IN VITRO STUDY; MEF AE GENE; MINIMUM INHIBITORY CONCENTRATION; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STREPTOCOCCUS AGALACTIAE;

ANTI-BACTERIAL AGENTS; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, BACTERIAL; ERYTHROMYCIN; GENES, BACTERIAL; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MULTIPLEX POLYMERASE CHAIN REACTION; STREPTOCOCCUS AGALACTIAE; TRIAZOLES;

EID: 84896842866     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02015-18     Document Type: Erratum

References (37)

1. Baker CJ. 2000. Group B streptococcal infections, p 222-237. In Stevens DL, Kaplan EL (ed), Streptococcal infections: clinical aspects, microbiology, and molecular pathogenesis. Oxford University Press, New York, NY.
2. Jackson LA, Hilsdon R, Farley MM, Harrison LH, Reingold AL, Plikaytis BD, Wenger JD, Schuchat A. 1995. Risk factors for group B streptococcal disease in adults. Ann. Intern. Med. 123:415-420. http://dx.doi.org/10.7326/0003-4819-123- 6-199509150-00003.
3. Heath PT, Balfour G, Weisner AM, Efstratiou A, Lamagni Tl, Tighe H, O'Connell LA, Cafferkey M, Verlander NQ, Nicoll A, McCartney AC, PHLS GBS Working Group. 2004.Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 363:292-294. http://dx.doi.org/10.1016/S0140- 6736(03)15389-5.
4. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK. 2002. Changes in pathogens causing early-onset sepsis in very low-birth weight infants. N. Engl. J. Med. 347:240-247. http://dx.doi.org/10.1056/NEJMoa012657. (Pubitemid 34787630)
5. Federal Register. 2013. Establishing a list of qualifying pathogens under the Food And Drug Administration Safety and Innovation Act. Proposed rule. Fed. Regist. 78:35155-35173.
6. Kimura K, Suzuki S, Wachino J, Kurokawa H, Yamane K, Shibata N, Nagano N, Kato H, Shibayama K, Arakawa Y. 2008. First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob. Agents Chemother. 52:2890-2897. http://dx.doi.org/10.1128/AAC.00185-08.
7. Nagano N, Nagano Y, Kimura K, Tamai K, Yanagisawa H, Arakawa Y. 2008. Genetic heterogeneity in pbp genes among clinically isolates group B streptococci with reduced penicillin susceptibility. Antimicrob. Agents Chemother. 52:4258-4267. http://dx.doi.org/10.1128/AAC.00596-08.
8. Borchardt S, DeBusscher JH, Tallman PA, Manning SD, Marrs CF, Kurzynski TA, Foxman B. 2006. Frequency of antimicrobial resistance among invasive and colonising group B streptococcal isolates. BMC Infect. Dis. 6:57-64. http://dx.doi.org/10.1186/1471-2334-6-57.
9. Pinheiro S, Radhouani H, Coelho C, Gonçalves A, Carvalho JA, Ruiz-Larrea F, Torres C, Igrejas G, Poeta P. 2009. Prevalence and mechanisms of erythromycin resistance in Streptococcus agalactiae from healthy pregnant women. Microb. Drug Resist. 15:121-124. http://dx.doi.org/10.1089/mdr.2009.0895.
10. Brinker AD, Wassel RT, Lyndly I, Serrano J, Avigan M, Lee WM, Seef LB. 2009. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 49:250-257. http://dx.doi.org/10.1002/hep. 22620.
11. Onur O, Guneysel O, Denizbasi A, Celikel C. 2007. Acute hepatitis attack after exposure to telithromycin. Clin. Ther. 29:1725-1729. http://dx.doi.org/10. 1016/j.clinthera.2007.08.004. (Pubitemid 47494541)
12. McGhee P, Clark C, Kosowska-Shick K, Nagai K, Dewasse B, Beachel L, Appelbaum PC. 2010. In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob. Agents Chemother. 54:230-238. http://dx.doi.org/10.1128/ AAC.01123-09.
13. Woosley LN, Castanheira M, Jones RN. 2010. CEM-101 activity against Gram-positive organisms. Antimicrob. Agents Chemother. 54:2182-2187. http://dx.doi.org/10.1128/AAC.01662-09.
14. Putnam SD, Castanheira M, Moet GJ, Farrell DJ, Jones RN. 2010. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagn. Microbiol. Infect. Dis. 66:393-401. http://dx.doi.org/10.1016/j.diagmicrobio.2009.10.013.
15. Imperi M, Pataracchia M, Alfarone G, Baldassari L, Orefici G, Creta R. 2010. A multiplex PCR assay for the direct identification of the capsular type (Ia to IX) of Streptococcus agalactiae. J. Microbiol. Methods 80:212-214. http://dx.doi.org/10.1016/j.mimet.2009.11.010.
16. Creti R, Fabretti F, Orefici G, von Hunolstein C. 2004. Multiplex PCR assay for direct identification of group B streptococcal α-protein-like protein genes. J. Clin. Microbiol. 42:1326-1329. http://dx.doi.org/10.1128/JCM. 42.3.1326-1329.2004. (Pubitemid 38332881)
17. Gygax SE, Schuyler JA, Kimmel LE, Trama JP, Mordechai E, Adelson ME. 2006. Erythromycin and clindamycin resistance in group B streptococcal clinical isolates. Antimicrob. Agents Chemother. 50:1875-1877. http://dx.doi.org/10.1128/ AAC.50.5.1875-1877.2006.
18. Clinical and Laboratory Standards Institute. 2010. Performance standard for antimicrobial susceptibility testing, M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
19. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40:2562-2566. (Pubitemid 26367644)
20. De Azavedo JCS, Yeung RH, Bast DJ, Duncan CL, Borgia SB, Low DE. 1999. Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada. Antimicrob. Agents Chemother. 43:2144-2147. (Pubitemid 29421191)
21. Desjardins M, Delgaty KL, Ramotar K, Seetaram C, Toye B. 2004. Prevalence and mechanisms of erythromycin resistance in group A and group B streptococcus: implications for reporting susceptibility results. J. Clin. Microbiol. 42:5620-5623. http://dx.doi.org/10.1128/JCM.42.12.5620-5623.2004. (Pubitemid 40003766)
22. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, M7-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
23. EUCAST. 2012. Breakpoint tables for interpretation of MICs and zone diameters, version 2.0. European Committee on Antimicrobial Susceptibility Testing. 2012. http://www.eucast.org/clinical-breakpoints/.
24. Dahesh S, Hensler ME, Van Sorge NM, Gertz RE, Jr, Schrag S, Nizet V, Beall BW. 2008. Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob. Agents Chemother. 52:2915-2918. http://dx.doi.org/10.1128/AAC.00461-08.
25. Florindo C, Viegas S, Paulino A, Rodrigues E, Gomes JP, Borrego MJ. 2010. Molecular characterization and antimicrobial susceptibility profiles in Streptococcus agalactiae colonizing strains: association of erythromycin resistance with subtype III-1 genetic clone family. Clin. Microbiol. Infect. 16:1458-1463. http://dx.doi.org/10.1111/j.1469-0691.2010.03106.x.
26. De Francesco MA, Caracciolo S, Gargiulo F, Manca N. 2012. Phenotypes, genotypes, serotypes and molecular epidemiology of erythromycin resistant Streptococcus agalactiae in Italy. Eur. J. Clin. Microbiol. Infect. Dis. 31:1741-1747. http://dx.doi.org/10.1007/s10096-011-1495-4.
27. Fluegge K, Supper S, Siedler A, Berner R. 2004. Antibiotic susceptibility in neonatal invasive isolates of Streptococcus agalactiae in a 2-year nationwide surveillance study in Germany. Antimicrob. Agents Chemother. 48: 4444-4446. http://dx.doi.org/10.1128/AAC.48.11.4444-4446.2004. (Pubitemid 39434912)
28. Gonzalez JJ, Andreu A, the Spanish Group for the Study of Perinatal infection from the Spanish Society for Microbiology and Infectious Diseases. 2005. Multicenter study of the mechanisms of resistance and clonal relationships of Streptococcus agalactiae isolates resistant to macrolides, lincosamides, and ketolides in Spain. Antimicrob. Agents Chemother. 49:2525-2527. http://dx.doi.org/10.1128/AAC.49.6.2525-2527.2005.
29. de Azavedo JC, McGavin M, Duncan C, Low DE, McGeer A. 2001. Prevalence and mechanisms of macrolide resistance in invasive and non-invasive group B streptococcus isolates from Ontario, Canada. Antimicrob. Agents Chemother. 45:3504-3508. http://dx.doi.org/10.1128/AAC.45.12.3504-3508.2001. (Pubitemid 33107869)
30. Fitoussi F, Loukil C, Gros I, Clermont O, Mariani P, Bonacorsi S, Le Thomas I, Deforche D, Bingen E. 2001. Mechanisms of macrolide resistance in clinical group B streptococci isolated in France. Antimicrob. Agents Chemother. 45:1889-1891. http://dx.doi.org/10.1128/AAC.45.6.1889-1891.2001. (Pubitemid 32466367)
31. Motlová J, Strakova L, Urbaskova P, Sak P, Sever T. 2004. Vaginal and rectal carriage of Streptococcus agalactiae in the Czech Republic: incidence, serotypes distribution and susceptibility to antibiotics. Indian J. Med. Res. 119:84-87. (Pubitemid 39004453)
32. Llano-Soleto B, Klepacki D, Mankinb AS. 2008. Binding and action of CEM-101, a new macrolide/ketolide in development for treating infections with macrolide-resistant and macrolide-susceptible bacteria, abstr. F-3983. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., 25 to 28 October 2008, Washington, DC.
33. Bingen E, Fitoussi F, Doit C, Cohen R, Tanna A, George R, Loukil C, Brahimi N, Le Thomas I, Deforche D. 2000. Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients. Antimicrob. Agents Chemother. 44:1453-1457. http://dx.doi.org/10.1128/AAC.44.6.1453-1457.2000. (Pubitemid 30340778)
34. Malhotra-Kumar S, Mazzariol A, Van Heirstraeten L, Lammens C, de Rijk P, Cornaglia G, Goossens H. 2009. Unusual resistance patterns in macrolide-resistant Streptococcus pyogenes harbouring ermA. J. Antimicrob. Chemother. 63:42-46. http://dx.doi.org/10.1093/jac/dkn432.
35. Lindahl G, Stalhammar-Carlemalm M, Areschoug T. 2005. Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens. Clin. Microbiol. Rev. 18:102-127. http://dx.doi.org/10.1128/CMR.18.1.102-127. 2005. (Pubitemid 40170663)
36. Quentin R, Huet H, Wang FS, Geslin P, Goudeau A, Selander RK. 1995. Characterization of Streptococcus agalactiae strains by multilocus enzyme genotype and serotype: identification of multiple virulent clone families that cause invasive neonatal disease. J. Clin. Microbiol. 33:2576-2581.
37. Gherardi G, Imperi M, Baldassarri L, Pataracchia M, Alfarone G, Recchia S, Orefici G, Dicuonzo G, Creti R. 2007. Molecular epidemiology and distribution of serotypes, surface proteins and antibiotic resistance in Italy. J. Clin. Microbiol. 45:2909-2916. http://dx.doi.org/10.1128/JCM.00999-07. (Pubitemid 47421999)